Biocon is currently trading at Rs. 291.00, down by 8.20 points or 2.74% from its previous closing of Rs. 299.20 on the BSE.
The scrip opened at Rs. 290.30 and has touched a high and low of Rs. 294.90 and Rs. 286.60 respectively. So far 44296 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 323.30 on 24-Feb-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 323.30 and Rs. 292.50 respectively. The current market cap of the company is Rs. 34926.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.
The US Food and Drug Administration (USFDA) has conducted a Post-Approval and GMP inspection of Biocon’s Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, between February 20 and February 26, 2020.
At the conclusion of the inspection the agency issued a Form 483, with two observations, which are procedural in nature. The company is confident of addressing these observations expeditiously and will respond to the FDA with a Corrective and Preventive Action Plan (CAPA) in a timely manner.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
